Matches in SemOpenAlex for { <https://semopenalex.org/work/W2091350416> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W2091350416 endingPage "683" @default.
- W2091350416 startingPage "673" @default.
- W2091350416 abstract "The human immunodeficiency virus (HIV-1) induces progressive and fatal disease in infected hosts. Initially the human immune response appears to control HIV infection. This hypothesis is supported by the long latency period observed during HIV infection prior to development of the active disease state. Similarly the observation of fetal protection from HIV infection in some pregnant women who have high titered neutralizing antibody responses to the virus underscores the importance of the humoral response to HIV in limiting infection. Therefore antibody replacement therapy is likely to provide substantial clinical benefits in this and other infected populations. However, currently there is no safe source for human antibodies with the desired protective qualities necessary for passive immune therapies. For a passive immune therapy to be valid it must protect against a diverse collection of viral isolates. Such a task is likely to require a complex mixture of human antibodies or human substitute antibodies which are available in large quantities and target conserved regions of the viral envelope, such that protection from diverse isolates are realized. Porcine products have been used extensively in many human therapeutic replacement regimens. Their use is primarily due to genetic similarity of the two species at the amino acid level which results in a high acceptance of grafted prosthetics and excellent tolerance of repeatedly administered biologicals. Accordingly we have examined the immunoglobulin responses to the Human Immunodeficiency Virus (HIV-1) of the Yorkshire mixed breed pig. Immunized animals developed significant humoral immunity as judged by ELISA, Western blot, radioimmunoprecipitation, flow microfluorimetry as well as in functional assays including neutralization and syncytia inhibition. The high neutralizing activity obtained and the immunological similarity between human and porcine immunoglobulin suggests that further investigation into the use of porcine immunoglobulin as human replacement antibodies for the therapeutic treatment of HIV is warranted." @default.
- W2091350416 created "2016-06-24" @default.
- W2091350416 creator A5007968062 @default.
- W2091350416 creator A5016371335 @default.
- W2091350416 creator A5031394625 @default.
- W2091350416 creator A5034902624 @default.
- W2091350416 creator A5086946489 @default.
- W2091350416 date "1991-12-01" @default.
- W2091350416 modified "2023-10-16" @default.
- W2091350416 title "Protective Humoral Immune Responses to the Human Immunodeficiency Virus Induced in Immunized Pigs: A Possible Source of Therapeutic Immunoglobulin Preparations" @default.
- W2091350416 cites W1639864449 @default.
- W2091350416 cites W2006869076 @default.
- W2091350416 cites W2039197539 @default.
- W2091350416 cites W2069243230 @default.
- W2091350416 cites W2080706877 @default.
- W2091350416 cites W2086369756 @default.
- W2091350416 cites W2145011997 @default.
- W2091350416 cites W2460053431 @default.
- W2091350416 cites W2280049778 @default.
- W2091350416 doi "https://doi.org/10.1089/hyb.1991.10.673" @default.
- W2091350416 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1816071" @default.
- W2091350416 hasPublicationYear "1991" @default.
- W2091350416 type Work @default.
- W2091350416 sameAs 2091350416 @default.
- W2091350416 citedByCount "0" @default.
- W2091350416 crossrefType "journal-article" @default.
- W2091350416 hasAuthorship W2091350416A5007968062 @default.
- W2091350416 hasAuthorship W2091350416A5016371335 @default.
- W2091350416 hasAuthorship W2091350416A5031394625 @default.
- W2091350416 hasAuthorship W2091350416A5034902624 @default.
- W2091350416 hasAuthorship W2091350416A5086946489 @default.
- W2091350416 hasConcept C159047783 @default.
- W2091350416 hasConcept C159654299 @default.
- W2091350416 hasConcept C203014093 @default.
- W2091350416 hasConcept C2522874641 @default.
- W2091350416 hasConcept C2776548049 @default.
- W2091350416 hasConcept C2779341262 @default.
- W2091350416 hasConcept C86803240 @default.
- W2091350416 hasConcept C8891405 @default.
- W2091350416 hasConceptScore W2091350416C159047783 @default.
- W2091350416 hasConceptScore W2091350416C159654299 @default.
- W2091350416 hasConceptScore W2091350416C203014093 @default.
- W2091350416 hasConceptScore W2091350416C2522874641 @default.
- W2091350416 hasConceptScore W2091350416C2776548049 @default.
- W2091350416 hasConceptScore W2091350416C2779341262 @default.
- W2091350416 hasConceptScore W2091350416C86803240 @default.
- W2091350416 hasConceptScore W2091350416C8891405 @default.
- W2091350416 hasIssue "6" @default.
- W2091350416 hasLocation W20913504161 @default.
- W2091350416 hasLocation W20913504162 @default.
- W2091350416 hasOpenAccess W2091350416 @default.
- W2091350416 hasPrimaryLocation W20913504161 @default.
- W2091350416 hasRelatedWork W1547625320 @default.
- W2091350416 hasRelatedWork W1964985474 @default.
- W2091350416 hasRelatedWork W1982142138 @default.
- W2091350416 hasRelatedWork W2027622304 @default.
- W2091350416 hasRelatedWork W2037826520 @default.
- W2091350416 hasRelatedWork W2152260884 @default.
- W2091350416 hasRelatedWork W2265125857 @default.
- W2091350416 hasRelatedWork W2373137085 @default.
- W2091350416 hasRelatedWork W3048051248 @default.
- W2091350416 hasRelatedWork W4200563690 @default.
- W2091350416 hasVolume "10" @default.
- W2091350416 isParatext "false" @default.
- W2091350416 isRetracted "false" @default.
- W2091350416 magId "2091350416" @default.
- W2091350416 workType "article" @default.